oral squamous cell carcinoma
Conditions
Interventions
experimental group:Camrelizumab+TP
Sponsors
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years,Gender is not limited; 2. Oral squamous cell carcinoma; 3. Always do not accept any system antitumor drugs; 4. ECOG = 12 weeks; 6. Patients with adequate organ function at the time of enrollment as defined below: (1) Blood routine examination standard (without blood transfusion within 14 days before enrollment): Hb >=90g/L; WBC>=3.0x10^9/L; ANC >=1.5x10^9/L; PLT >=80x10^9/L; (2) Biochemical examination shall meet the following standards: BIL 50ml/min (Cockcroft-Gault math); 7. Women of childbearing age in the serum or urine pregnancy test is negative within 7 days prior to study enrollment and must be Non-lactating patients and agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 8 months after the end of the study males should agree to patients who must use contraception during the study period and within 12 months after the end of the study period; 8. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have received anti-tumor treatment in the past; 2. The patient has any active autoimmune disease or a history of autoimmune disease; 3. Patients who cannot complete the necessary treatment plan and follow-up observation; 4. Other situations in which investigators thought the patients not suit to be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free survival;side effecs;Duration of Response; | — |
Countries
China
Contacts
Public ContactRen Guoxin
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed